Selskabsmeddelelser

Capital increase of 360,000 shares in Orphazyme A/S as a result of the utilization of the U.S. At-the-Market Offering Program

Feb 18, 2022

Orphazyme A/S (ORPHA.CO (DK); ORPH (US)) (the “Company”), a late-stage biopharmaceutical company, announces that the Company has issued new shares in the period from Friday, February 11, 2022 to Thursday, February 17, 2022 as a result of the utilization of the Company’s U.S. At-the-Market Offering Program with Cowen and Company, LLC (“Cowen”). On February 11, 2022, a total of 360,000 ordinary shares of nominally DKK 1 each, represented by American Depositary Shares (“ADSs”), have been issued by the Company and sold in the market by Cowen as the sales agent at market price as determined by the Company’s Board of Directors in accordance with the authorization in article 3.1 of the Company’s Articles of Association.

Capital increase of 360000 shares in Orphazyme as a result of the utilization of the U.S. ATM Offering Program

Read more

Resolutions passed at the Extraordinary General Meeting

Feb 15, 2022

Orphazyme A/S (ORPHA.CO; ORPH) (“Orphazyme” or the “Company”), a late-stage biopharmaceutical company pioneering the Heat-Shock Protein response for the treatment of neurodegenerative orphan diseases, today held an Extraordinary General Meeting, at which the general meeting.

Resolutions passed at the Extraordinary General Meeting

Read more

Amendment of proposals put forward at the Extraordinary General Meeting

Feb 14, 2022

Orphazyme A/S (ORPHA.CO; ORPH) (“Orphazyme” or the “Company”), a late-stage biopharmaceutical company pioneering the Heat-Shock Protein response for the treatment of neurodegenerative orphan diseases, today announced that the Board of Directors has decided to limit the scope of the proposed authorizations set forward under items 1.2, 1.3 and 1.4 of the agenda of the Extraordinary General Meeting to be held tomorrow, February 15, 2022.

Amendment of proposals put forward at the Extraordinary General Meeting

Read more

Orphazyme provides update for planned NDA resubmission for arimoclomol for the treatment of Niemann-Pick disease type C in the United States

Feb 11, 2022

Orphazyme A/S (ORPHA.CO; ORPH) (“Orphazyme” or the “Company”), a late-stage biopharmaceutical company pioneering the Heat-Shock Protein response for the treatment of neurodegenerative orphan diseases, today provides an update on the process and anticipated timelines for resubmission of its New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for investigational product candidate, arimoclomol, for the treatment of Niemann-Pick disease type C (NPC).

Orphazyme provides update for planned NDA resubmission for arimoclomol for the treatment of Niemann-Pick disease type C in the United States

Read more

Orphazyme to present additional data on arimoclomol’s mechanism of action during 2022 Annual WORLDSymposium™

Feb 7, 2022

Orphazyme A/S (ORPHA.CO; ORPH) (“Orphazyme” or the “Company”), a late-stage biopharmaceutical company pioneering the Heat-Shock Protein response for the treatment of neurodegenerative orphan diseases, today announced it will present new non-clinical data on its investigational drug arimoclomol during the 18th Annual WORLDSymposium™ Scientific Meeting, to be held in San Diego, CA and virtually on February 7-11, 2022.

Orphazyme to present additional data on arimoclomol’s mechanism of action during 2022 Annual WORLDSymposium™

Read more

Changes to the Executive Management of Orphazyme – Anders Vadsholt to be appointed CEO

Jan 31, 2022

Orphazyme A/S (ORPHA.CO; ORPH) (“Orphazyme” or the “Company”), a late-stage biopharmaceutical company pioneering the Heat-Shock Protein response for the treatment of neurodegenerative orphan diseases, today announces that Chief Executive Officer (CEO) Christophe Bourdon will resign from his position as CEO at Orphazyme A/S to take on the role as CEO of LEO Pharma A/S. Effective April 1, 2022, Chief Financial Officer (CFO), Anders Vadsholt, will be appointed CEO of Orphazyme.

Changes to the Executive Management of Orphazyme

Read more

Notice to convene Extraordinary General Meeting

Jan 24, 2022

Orphazyme A/S (ORPHA.CO; ORPH) (the “Company”), a late-stage biopharmaceutical company pioneering the Heat-Shock Protein response for the treatment of neurodegenerative orphan diseases, today announced that an Extraordinary General Meeting of the Company will be held on.

Notice to convene Extraordinary General Meeting

Appendix 1 Candidate for the Board of Directors

Message to shareholders

Read more

Orphazyme updates 2021 financial outlook

Jan 18, 2022

Orphazyme A/S (ORPHA.CO; ORPH or the “Company”), a late-stage biopharmaceutical company, today announces an update to its financial outlook for 2021 based on a review of preliminary unaudited financial results for the year ending December 31, 2021. Audited financial results for the full-year 2021 will be published on March 15, 2022.

Orphazyme updates 2021 financial outlook

Read more

1 2 3 4